Wells Fargo & Company MN raised its position in Cambrex Co. (NYSE:CBM) by 15.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 341,819 shares of the biotechnology company’s stock after purchasing an additional 45,325 shares during the period. Wells Fargo & Company MN owned 1.04% of Cambrex worth $16,407,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Polaris Capital Management LLC grew its position in shares of Cambrex by 14.4% in the 4th quarter. Polaris Capital Management LLC now owns 24,482 shares of the biotechnology company’s stock valued at $1,954,000 after buying an additional 3,085 shares during the last quarter. Swiss National Bank grew its position in shares of Cambrex by 4.8% in the 4th quarter. Swiss National Bank now owns 57,000 shares of the biotechnology company’s stock valued at $2,736,000 after buying an additional 2,600 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Cambrex by 5.1% in the 4th quarter. California Public Employees Retirement System now owns 81,515 shares of the biotechnology company’s stock valued at $3,913,000 after buying an additional 3,949 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Cambrex in the 4th quarter valued at $541,000. Finally, Palouse Capital Management Inc. grew its position in shares of Cambrex by 32.5% in the 4th quarter. Palouse Capital Management Inc. now owns 5,436 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 1,333 shares during the last quarter.
Cambrex Co. (CBM) opened at $56.15 on Wednesday. Cambrex Co. has a 52-week low of $42.55 and a 52-week high of $62.95. The stock has a market cap of $1,836.14, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 1.35 and a beta of 2.38.
Cambrex (NYSE:CBM) last issued its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.17. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The company had revenue of $182.28 million for the quarter, compared to the consensus estimate of $181.39 million. During the same period last year, the firm posted $1.23 EPS. Cambrex’s revenue for the quarter was up 2.5% on a year-over-year basis. analysts anticipate that Cambrex Co. will post 2.76 EPS for the current year.
A number of research analysts recently commented on CBM shares. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Longbow Research downgraded shares of Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. Finally, William Blair started coverage on shares of Cambrex in a research report on Tuesday, January 16th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $60.00.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/14/cambrex-co-cbm-holdings-raised-by-wells-fargo-company-mn.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.